74
After the EU approval in April this year, Eisai has now set up a program for controlled access in Germany and announces the availability from September 1st. »To ensure the safe and effective use of Lecanemab and the admission -compliant application
To support, all prescribers and patients must be registered in a program for controlled access before the start of treatment, «said the manufacturer. In addition to Austria, Germany is the first country in the EU where the medication will be available. The market was launched in the neighboring country yesterday.
